The primary objective of this multicentre study was to evaluate the safety and tolerability durvalumab (Du), a PD-L1 inhibitor, (Tr), a CTLA-4 inhibitor, in combination with one of four standard platinum-doublet regimens (pemetrexed (pem), gemcitabine (gem), etoposide (etop) and nab-paclitaxel (nabP) with carboplatin), in order to establish a recommended phase II dose (R2PD) for each combination.

**METHODS**

- **Patients** (pts) with advanced solid tumours, regardless of tumour PD-L1 status or number of prior therapies, were enrolled into one of four cohorts.
- Dose level (DL) 0 added Du 15 mg/m² q3wk + Tr 1 mg/kg x1; DL1=Du 15 mg/m² q3wk + Tr 1mg/kg x1; DL2a=Du 15mg/kg q3wk + Tr 3mg/kg q6wk x multiple doses; DL2b=Du 15mg/kg q3wk + Tr 1 mg/kg x1, Du 15mg/kg q3wk + Tr 3 mg/kg q6wk x multiple doses.
- RESULTS: Seventy-eight pts (median age 60 (range 30-80); 51% male, 95% EGFR/19-TP53- mutated of which 52% were chemotherapy. Thus far 285 cycles have been administered. Across dose levels, the majority of drug-related adverse events (AEs) were Grade 1. AE rates varied across dose levels, though attribution of some AEs could be either chemotherapy or immune-related (nausea, hepatotoxicity, skin, AND pulmonary toxicity). AE rates could be investigated relative to either Du or Tr.

- 1 dose of tremelimumab is given after doublet chemotherapy has been administered. One dose of tremelimumab should be given every 4 weeks.

**ADVERSE EVENTS**

- Grade 3/4 AEs of tremelimumab were reported in 6% of patients (pem) and 9% of patients (gem).

**CONCLUSIONS**

- In this PD-L1 unselected patient population, Du 15mg/kg q3w and T 3mg/kg q6w has to date been safely combined platinum-doublet chemotherapy.
- Most AEs were attributable to chemotherapy though attribution of some AEs could be either chemotherapy or immune-related (renal, hepatic, skin and pulmonary toxicity).
- AEs that were considered to be related to tremelimumab included hypertension, diarrhea, disorders of the respiratory system and dermatologic toxicity, and were generally Grade 1 or 2. No cases of Grade 3 or 4 were reported.

- Expansion cohorts are planned at the RP2D.